European Social Partners remind European co-legislators about their statement on inclusion of Hazardous Medicinal Products in the Carcinogens and Mutagens Directive (CMD)
In the context of the ongoing trialogue on the fourth revision of the CMD (2004/37/EC), HOSPEEM and EPSU would like to highlight the need to include hazardous medicinal products as a new entry in CMD Appendix I.